NLS Aerocrine

Aerocrine AB announced that board member Staffan Lindstrand resigned. Lindstrand is also a board member of Healthcap, where he also is a partner, pharmaceutical company Orexo, Medtech company Pulmonx and eye laser company 20/10 Perfect Vision. He is a civil engineer with 10 years of experience in investment banking. Prior to this announcement, Aerocrine also […]

The aim is to test secure, cloud-based remote medical device monitoring. Through the collaboration Aerocrine will utilize Microsoft’s cloud services to transmit device telemetry data from physician and company sites in Sweden, UK and US back to Aerocrine for analyses. “The ability to collect vital telemetry data from deployed devices has been a key objective of […]

Aerocrine has announces the signing of an exclusive agreement with UK & Irish medical device company Healthcare 21 for sales, marketing and distribution of Aerocrine’s new airway inflammation monitor and test kit – NIOX VERO – across the UK and Ireland. The agreement goes into effect on February 1, 2014 and gives Healthcare 21 exclusive […]

Swedish Aerocrine AB has announced that the Japanese authority has approved the FeNO measuring device Niox Mino. On 28 of March 2013 the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) decided to grant the 2008 version of the Niox Mino marketing approval in Japan. As Aerocrine introduced a new version in 2010 of the product, […]

Swedish Medtech Company Aerocrine was formed in 1997, based on research conducted at the Karolinska Institute investigating nitric oxide (NO) as an indicator for inflammatory processes, such as asthma. Aerocrine has developed devices to measure nitric oxide in exhaled air and these are used to both diagnose and follow the treatment of asthma. Aerocrine does […]

Aerocrine’s NIOX MINO device for measuring FeNO receives approval by Health Canada.